Potential impact of immunobiotechnology on cancer therapy
- 1 August 1987
- journal article
- review article
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 74 (8), 705-710
- https://doi.org/10.1002/bjs.1800740820
Abstract
Genetic engineering techniques allow large scale production of substances generated during the immune response and these may have therapeutic value by modifying the biological response to cancer.Keywords
This publication has 55 references indexed in Scilit:
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- Diagnosis and therapy with labeled antibodiesImmunology Today, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factorEuropean Journal of Biochemistry, 1985
- Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxinNature, 1984
- Interleukin 2: the molecule and its functionImmunology Today, 1984
- Effect of Recombinant Alpha Interferon on NK and ADCC Function in Lung Cancer Patients: Results from a Phase II TrialJournal of Interferon Research, 1984
- The structure of eight distinct cloned human leukocyte interferon cDNAsNature, 1981
- Induction and kinetics of natural killer cells in humans following interferon therapyNature, 1979
- Immunological profile of breast cancer patients in early or advanced diseaseCellular and Molecular Life Sciences, 1979